17th September 2026: MetaQon Precision Health today announced the India rollout of MetaQon Reproductive Intelligence, a pre-cycle fertility workup built to flag the genetic and biological risk factors that standard first-line IVF testing routinely misses. The offering is built on whole-genome technology and is designed for use by fertility clinics before a couple commits to a cycle, not after one has failed.
India now runs among the highest volumes of IVF cycles in the world, and industry estimates put the number at roughly 200,000 to 300,000 cycles a year. Almost none of that cost is picked up by anyone but the couple. IVF is not part of India’s public hospital system in any general sense, and standard health insurance does not cover it either: IRDAI requires insurers to disclose their exclusions clearly but does not mandate fertility coverage, so IVF, IUI and ICSI remain standard exclusions unless a couple buys a specific rider, which is uncommon and comes capped. A single cycle at a private clinic commonly runs ₹1.5 to ₹3.5 lakh depending on the city, and most fertility specialists advise budgeting for two to three cycles before reassessing the approach. That can push a couple’s total spend past ₹5 lakh, financed in many cases on EMI, against reported per-cycle success rates that fall from roughly 35 to 45 percent under age 35 to well under 20 percent after 38.
The problem MetaQon is addressing is not a lack of testing. It is that standard pre-cycle panels can look normal while a genetic predisposition is quietly working against the couple, for example an inherited clotting disorder (a genetic tendency toward blood clots that can interfere with implantation), a methylation defect (a common genetic variant that affects how the body processes folate and B vitamins needed for healthy embryo development), or sperm DNA fragmentation (damage inside the sperm’s genetic material that a standard semen analysis does not pick up, since that test only looks at count and movement). MetaQon Reproductive Intelligence closes that gap by reading both partners’ whole-genome data against reproductive genes, confirming with a targeted blood biomarker panel whether a flagged risk is currently active, and cross-checking that against a structured symptom review. The result is a ranked, clinic-ready order set the couple’s doctor can act on, rather than another report they have to interpret on their own.
“A genetic report on its own tells a couple they carry a risk. It does not tell the clinician what to do about it before the next cycle,” said Yashpal Jain, Co-Founder and CEO of MetaQon Precision Health. “We built Reproductive Intelligence to close that distance, so a clinic can order the right confirmatory test and have the right conversation with a couple in the same visit, months before a cycle would otherwise fail for a reason nobody checked for.”
The intended audience is twofold: fertility clinics and IVF specialists across India who are looking for a defensible, repeatable way to prioritize pre-cycle workups across every center they run, and the couples in their care, for whom a failed cycle is rarely only a clinical setback. It is also a financial one, often absorbed through savings or EMI, and an emotional one that a delay of even a single cycle can compound, particularly for women in their late thirties for whom ovarian reserve is declining month over month.
The cost of not screening for this earlier is the cost of finding out the hard way. A couple who proceeds on a normal semen analysis and a normal first-line hormone panel, while carrying an unflagged thrombophilia or methylation variant, is not protected by those normal results. They are simply not yet aware of what is working against them. MetaQon’s case for the workup is that the same information used to explain a failed cycle after the fact can instead be used to change the plan before it, at a fraction of the cost of repeating one.
MetaQon Reproductive Intelligence is available now to fertility clinics in India, drawing on CLIA-certified and CAP-accredited laboratory partners to process the underlying whole-genome analysis. Clinics interested in adopting the workup for their pre-cycle protocol can reach MetaQon through the contact details below.
Genetic results are risk-stratification information. They are not diagnostic, and they support, rather than replace, clinical judgment.
ABOUT METAQON PRECISION HEALTH
MetaQon exists to make precision health usable, not just available. Genomics, biomarker science and AI-powered interpretation already exist; what has been missing is a clear line from a person’s own biology to a decision their doctor can act on. MetaQon builds that line, across cardiovascular, metabolic, neurological, reproductive and other areas of health, working with hospitals, fertility clinics and specialists across India, the GCC and APAC/MENA to turn genetic and biomarker findings into a defensible, clinic-ready next step rather than another report a patient has to interpret alone. MetaQon Precision Health Inc. is incorporated in Delaware; MetaQon FZC operates from the Sharjah Research Technology and Innovation Park (SRTIP) Free Zone, UAE. Learn more at metaqon.com.
